Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir

Journal of Clinical Pharmacology

Volumn 38, Issue 2, 1998, Pages 106-111

  Von Moltke, Lisa L ^a,c   Greenblatt, David J ^a   Grassi, Jeffrey M ^a   Granda, Brian W ^a   Duan, Su Xiang ^a   Fogelman, Steven M ^a,d   Daily, Johanna P ^b   Harmatz, Jerold S ^a   Shader, Richard I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c National Institutes of Mental Health

^d Amer Coll N

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; ANTIVIRUS AGENT; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DESIPRAMINE; DEXTROMETHORPHAN; DIETHYLDITHIOCARBAMIC ACID; FLUOXETINE; INDINAVIR; KETOCONAZOLE; MEPHENYTOIN; NELFINAVIR; PHENACETIN; PROTEINASE INHIBITOR; QUINIDINE; RITONAVIR; SAQUINAVIR; SULFAPHENAZOLE; TOLBUTAMIDE; TRIAZOLAM;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER MICROSOME;

EID: 0031931102     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04398.x     Document Type: Article

References (31)

1. Deeks SG, Smith M, Holodniy M, Kahn JO: HIV-1 protease inhibitors: a review for clinicians. JAMA 1997;277:145-153.
2. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al: Antiretrovial therapy for HIV infection in 1997. JAMA 1997;277:1962-1969.
3. McDonald CK, Kuritzkes DR: Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med 1997;157:951-959.
4. Sahai J: Risks and synergies from drug interactions. AIDS 1996;10(suppl 1):S21-S25.
5. Barry M, Gibbons S, Back D, Mulcahy F: Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997;32:194-209.
6. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H: Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:685-693.
7. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, et al: Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacol 1996;128:398-407.
8. Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI: Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin para-hydroxylation. Br J Clin Pharmacol 1997;44:495-498.
9. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Duan SX, Karsov D, Shader RI: Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. Pharmacology 1996; 52:125-134.
10. Schmider J, Greenblatt DJ, Fogelman SM, von Moltke LL, Shader RI: Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6, 3A3/4, with a possible role of 2E1. Biopharmaceut Drug Dispos 1997;18:227-240.
11. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI: Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-1283.
12. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI: Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-131.
13. Court MH, von Moltke LL, Shader RI, Greenblatt DJ: Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharmaceut Drug Dispos 1997;18:213-226.
14. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, et al: Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-379.
15. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI: Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998;38:112-121.
16. Newton DJ, Wang RW, Lu AYH: Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23:154-158.
17. Parkinson A: An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 1996;24:45-57.
18. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI: In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998;55:113-122.
19. Bertz RJ, Granneman GR: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-258.
20. Shader RI, von Moltke LL, Schmider J, Harmatz JS, Greenblatt DJ: The clinician and drug interactions: an update. J Clin Psychopharmacol 1996;16:197-201.
21. Eagling VA, Back DJ, Barry MG: Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-194.
22. Kumar GN, Rodrigues AD, Buko AM, Denissen JF: Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996;277:423-431.
23. Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH: Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996;24:307-314.
24. Chiba M, Hensleigh M, Lin JH: Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Biochem Pharmacol 1997;53:1187-1195.
25. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI: Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995;29(suppl 1):33-43.
26. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
27. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-1878.
28. Schmider J, Greenblatt DJ, von Moltke LL, Shader RI: Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J Clin Psychopharmacol 1996;16:267-272.
29. Fitzsimmons ME, Collins JM: Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Drug Metab Dispos 1997;25:256-266.
30. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, et al: Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997;41:654-660.
31. Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tjia JF, et al: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997;11:F29-F33.